Larimar Therapeutics, Inc.
Congressional Trades
No congressional trades in LRMR on record.
Whale Activity
- Increased50
- New13
- Held28
- Decreased55
- Closed29
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. | 35.6M | $113.8M | held |
| Blue Owl Capital Holdings LP | 9.9M | $31.7M | increased |
| RTW INVESTMENTS, LP | 5.8M | $18.6M | increased |
| BlackRock, Inc. | 5.8M | $18.4M | increased |
| Defilade Capital Management, L.P. | 4.9M | $15.8M | increased |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 3.1M | $10.0M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $9.5M | held |
| GOLDMAN SACHS GROUP INC | 3.0M | $9.5M | increased |
| AQR CAPITAL MANAGEMENT LLC | 2.2M | $7.2M | decreased |
| MARSHALL WACE, LLP | 2.2M | $7.0M | increased |
| DAFNA Capital Management LLC | 1.9M | $6.0M | decreased |
| BANK OF AMERICA CORP /DE/ | 1.9M | $6.0M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Clayton RussellChief Medical Officer | Purchase | +3,322 | $3.01 | $10K | Nov 16, 2026 | Form 4 ↗ |
| SHERMAN JEFFREY WDirector · Director | Purchase | +3,289 | $3.06 | $10K | Nov 16, 2026 | Form 4 ↗ |
| Hamilton Thomas EdwardDirector · Director | Purchase | +70.0K | $2.67 | $187K | Nov 12, 2026 | Form 4 ↗ |
| BEN-MAIMON CAROLEPresident and CEO · Director | Purchase | +18.1K | $2.77 | $50K | Nov 11, 2026 | Form 4 ↗ |
| THOMAS FRANK EDirector · Director | Purchase | +8,000 | $2.73 | $22K | Nov 11, 2026 | Form 4 ↗ |
| Truitt JosephDirector · Director | Purchase | +3,500 | $2.80 | $10K | Nov 11, 2026 | Form 4 ↗ |
| Harlow John B. Jr.President and COO | Purchase | +17.8K | $2.80 | $50K | Nov 11, 2026 | Form 4 ↗ |
| Celano MichaelChief Financial Officer | Purchase | +18.5K | $2.71 | $50K | Nov 11, 2026 | Form 4 ↗ |
| Shankar GopiChief Development Officer | Purchase | +5,000 | $2.71 | $14K | Nov 11, 2026 | Form 4 ↗ |
| Hamilton Thomas EdwardDirector | Purchase | +50.0K | $3.34 | $167K | Jul 6, 2026 | Form 4 ↗ |
| Deerfield Mgmt HIF, L.P.Director · 10% owner | Purchase | +2.0M | $5.00 | $10.0M | Feb 27, 2026 | Form 4 ↗ |
| Deerfield Mgmt HIF, L.P.Director · 10% owner | Purchase | +832.0K | $5.00 | $4.2M | Feb 27, 2026 | Form 4 ↗ |
| Deerfield Mgmt HIF, L.P.Director · 10% owner | Purchase | +1.1M | $5.00 | $5.4M | Feb 27, 2026 | Form 4 ↗ |
| Deerfield Mgmt HIF, L.P.Director · 10% owner | Purchase | +1.1M | $5.00 | $5.4M | Feb 27, 2026 | Form 4 ↗ |
| Hamilton Thomas EdwardDirector | Purchase | +100.0K | $5.00 | $500K | Feb 27, 2026 | Form 4 ↗ |
| THOMAS FRANK EDirector | Purchase | +5,000 | $5.00 | $25K | Feb 27, 2026 | Form 4 ↗ |
| SHERMAN JEFFREY WDirector | Purchase | +5,000 | $5.00 | $25K | Feb 27, 2026 | Form 4 ↗ |
| Shankar GopiChief Development Officer | Grant / award | +25.6K | $0.00 | $0 | Jan 26, 2026 | Form 4 ↗ |
| Clayton RussellChief Medical Officer | Grant / award | +25.6K | $0.00 | $0 | Jan 26, 2026 | Form 4 ↗ |
| BEN-MAIMON CAROLEPresident and CEO · Director | Grant / award | +100.1K | $0.00 | $0 | Jan 26, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $6.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.7M | $5.3M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 726.5K | $2.8M | 0.01% | Jul 31, 2026 |
| VANGUARD EXPLORER FUND | 659.1K | $2.5M | 0.01% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF Fidelity Covington Trust | 814.6K | $2.5M | 0.04% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 757.6K | $2.3M | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 699.5K | $2.1M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 625.2K | $1.9M | 0.01% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 382.5K | $1.5M | 0.01% | Aug 31, 2026 |
| Dimensional U.S. Small Cap ETF Dimensional ETF Trust | 340.8K | $1.3M | 0.01% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list LRMR's shares (CUSIP 517125100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Roderick WongSCHEDULE 13G · passive (13G) · 5.8M shares5.6%
Nov 16, 2026 · ↗ - RTW Investments, LPSCHEDULE 13G · passive (13G) · 5.8M shares5.6%
Nov 16, 2026 · ↗ - Blue Owl Capital Holdings LPSCHEDULE 13G/A · passive (13G) · 10.7M shares10.0%
May 14, 2026 · ↗ - Israel A. EnglanderSCHEDULE 13G/A · passive (13G) · 3.6M shares3.5%
Apr 30, 2026 · ↗ - Millennium Group Management LLCSCHEDULE 13G/A · passive (13G) · 3.6M shares3.5%
Apr 30, 2026 · ↗ - Millennium Management LLCSCHEDULE 13G/A · passive (13G) · 3.6M shares3.5%
Apr 30, 2026 · ↗ - GOLDMAN SACHS & CO. LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares4.1%
May 13, 2025 · ↗ - THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G/A · passive (13G) · 2.6M shares4.1%
May 13, 2025 · ↗
Corporate Lobbying
No lobbying filings found naming Larimar Therapeutics, Inc. as the client.
Government Contracts
No federal contract awards found for Larimar Therapeutics, Inc..
U.S. Patents
No USPTO patent applications found for Larimar Therapeutics, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| Diluted EPS | n/a | -$1.32 | -$0.84 | -$1.37 | -$2.95 |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Cash and equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
| Shareholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M |
As Larimar Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗
Stock Splits
- 1-for-12Reverse splitMay 29, 2020
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsNov 9, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsAug 4, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 19, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsMay 14, 2026
EDGAR ↗
